Protein Aggregation and the Development of NU-9 (aka AKV9) for ALS by Dr. Richard Silverman

Dr. Richard Silverman is the Patrick G. Ryan/Aon professor in the Department of Chemistry at Northwestern University. He is the inventor of the blockbuster drug Lyrica, marketed by Pfizer. He has another drug licensed to Ovid Therapeutics in clinical trials for epilepsy, and a drug from his own company, Akava Therapeutics, for which the IND application will be filed in May for the treatment of ALS. He has published almost 400 research papers, written five books, and is an inventor on 130 issued patents. Recently, he was elected to the National Academy of Sciences.
Dr. Ozdinler received training in the fields of molecular biology, genetics, biotechnology, cell biology, anatomy and neuroscience. She is the recipient of Harvard NeuroDiscovery Center and NUCATS Translational Innovation awards. She was recruited to be the founding director of the 2nd Les Turner ALS Laboratory at Northwestern, which focused on the biology and pathology of upper motor neurons. She is now a faculty member at the Chemistry Life Sciences Processes Institute, Les Turner ALS, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, and Robert H. Lurie Comprehensive Cancer Research Centers.